公开(公告)号：US20030152912A1

公开(公告)日：2003-08-14

申请号：US10060941

申请日：2002-01-29

Inventor： Julie Dyall ,  Charles P. Romano ,  Paul D. Olivo ,  Robert M. Roth

IPC: C12Q001/70 ,  G01N033/53 ,  A61K031/70 ,  A01N043/04 ,  C12P019/34 ,  C12N007/00 ,  C12N007/01

CPC classification number: G01N33/502 ,  G01N33/5008 ,  G01N2500/10

Abstract: Methods and compositions are provided for screening candidate antiviral agents using cells containing subgenomic viral replication systems such as replicons and minigenomes. The methods involve the simultaneous assay of more than one subgenomic viral replication system. Compositions useful for these methods are also provided.

Abstract translation: 提供了使用含有亚基因组病毒复制系统（例如复制子和小基因组）的细胞筛选候选抗病毒剂的方法和组合物。 该方法涉及同时测定多于一个亚基因组病毒复制系统。 还提供了对这些方法有用的组合物。

公开(公告)号：US20030143573A1

公开(公告)日：2003-07-31

申请号：US10217240

申请日：2002-08-09

Inventor： Roy Huchzermeier ,  Edward Joseph Dubovi

IPC: C12Q001/70 ,  C12Q001/68 ,  G01N033/53 ,  C12N007/00 ,  C12N007/01

CPC classification number: G01N33/56983 ,  C07K16/1081 ,  G01N2333/18

Abstract: The present invention relates to a method of detecting whether a target animal is Bovine Viral Diarrhea Virus (BVDV) positive or negative by determining whether a gp48 protein-specific reagent binds to a gp48 Bovine Viral Diarrhea Virus protein or protein fragment, which retains antigenic specificity, from a target animal's tissue sample.

Abstract translation: 本发明涉及通过确定gp48蛋白特异性试剂是否与gp48牛病毒性腹泻病毒蛋白质或蛋白质片段结合来检测目标动物是牛病毒性腹泻病毒（BVDV）是否为阳性或阴性的方法，其保留抗原特异性 ，来自目标动物的组织样品。

公开(公告)号：US20030138922A1

公开(公告)日：2003-07-24

申请号：US10058480

申请日：2002-01-24

Inventor： William John Martin

IPC: C12Q001/70 ,  C12P001/00 ,  C12N013/00 ,  C12N007/00 ,  C12N007/01

CPC classification number: C12Q1/705

Abstract: A method of causing irreversible damage to stealth virus infected cells, based on exposing the infected cells to magnetic energy. The method of the present application specifically relates to the culturing of stealth viruses from an infected subject and determining the presence of magnetic and/or paramagnetic material in the stealth virus infected culture. Magnetic and/or paramagnetic material can also be found in cultures of bacteria that are infected with the patient's stealth virus. The cultured stealth virus infected cells are tested for susceptibility to cell damage caused by a magnetic field that is not significantly injurious to normal uninfected cells. The presence of magnetic and/or paramagnetic material in the stealth virus culture and the demonstration that exposure to a strong magnetic field can cause damage to stealth virus infected cells, form the basis of therapy for stealth virus infected patients and animals. The therapy comprises exposing stealth virus infected cells within a patient to a magnetic field of sufficient strength to cause damage to cultured virus infected cells. Magnetic energy therapy is especially applicable as therapy for stealth virus associated cancers in which the stealth virus isolated from the cancer patient can be shown to induce the formation of magnetic and/or paramagnetic material.

Abstract translation: 基于将受感染的细胞暴露于磁能，引起隐形病毒感染细胞的不可逆损伤的方法。 本申请的方法具体涉及从受感染的受试者中培养隐形病毒并确定隐形病毒感染培养物中磁性和/或顺磁材料的存在。 磁性和/或顺磁性材料也可以在被病毒隐形病毒感染的细菌培养物中发现。 测试培养的隐形病毒感染细胞对不受正常未感染细胞显着损伤的磁场引起的细胞损伤的易感性。 在隐形病毒培养物中存在磁性和/或顺磁材料，并且证明暴露于强磁场可能会对隐形病毒感染的细胞造成伤害，形成隐形病毒感染患者和动物的治疗基础。 该疗法包括将患者内的隐形病毒感染的细胞暴露于具有足够强度的磁场以对培养的病毒感染的细胞造成损害。 磁能治疗特别适用于隐形病毒相关癌症的治疗，其中可以显示从癌症患者分离的隐形病毒诱导形成磁性和/或顺磁性材料。

公开(公告)号：US20030129744A1

公开(公告)日：2003-07-10

申请号：US10312062

申请日：2002-12-20

Inventor： Tobias Schlapp ,  Franciscus Antonius Maria Rijsewijk

IPC: C12Q001/70 ,  A61K039/12 ,  C12N007/00 ,  C12N005/06 ,  C12N007/01 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C12N005/00 ,  C12N005/02

CPC classification number: C07K14/005 ,  A61K2039/5256 ,  A61K2039/5258 ,  C12N7/00 ,  C12N2770/24322 ,  C12N2770/24323

Abstract: The present invention relates to bovine viral diarrhea virus (BVDV) virus-like particles, a polycistronic RNA and DNA corresponding thereto encoding a polyprotein of BVDV structural proteins that are sufficient to form BVDV virus-like particles, a viral vector encoding factors and structural proteins for the assembly of BVDV virus-like particles, a vaccine comprising BVDV virus-like particles, a diagnostic kit and methods for preparing BVDV virus-like particles.

Abstract translation: 本发明涉及牛病毒性腹泻病毒（BVDV）病毒样颗粒，多顺反子RNA和与之对应的DNA，其编码足够形成BVDV病毒样颗粒的BVDV结构蛋白的多蛋白，编码因子和结构蛋白的病毒载体 用于组装BVDV病毒样颗粒，包含BVDV病毒样颗粒的疫苗，诊断试剂盒和用于制备BVDV病毒样颗粒的方法。

公开(公告)号：US20030129727A1

公开(公告)日：2003-07-10

申请号：US10270846

申请日：2002-10-11

Applicant: Prokaria ltd.

Inventor： Sigridur Hjorleifsdottir ,  Gudmundur O. Hreggvidsson ,  Olafur H. Fridjonsson ,  Arnthor Aevarsson ,  Jakob K. Kristjansson

IPC: C12Q001/68 ,  C12P021/06 ,  C12P019/34 ,  C12N007/00 ,  C12N007/01

CPC classification number: C07K14/005 ,  C12N7/00 ,  C12N2795/10121 ,  C12N2795/10122 ,  Y10T436/143333

Abstract: A novel bacteriophage RM 378 of Rhodothermus marinus, the nucleic acids of its genome, nucleic acids comprising nucleotide sequences of open reading frames (ORFs) of its genome, and polypeptides encoded by the nucleic acids, are described.

Abstract translation: 描述了Rhodothermus marinus的新型噬菌体RM378，其基因组的核酸，其包含其基因组的开放阅读框（ORF）的核苷酸序列的核酸和由核酸编码的多肽。

公开(公告)号：US20030124650A1

公开(公告)日：2003-07-03

申请号：US10006223

申请日：2001-12-10

Inventor： Artur Mitterer ,  Christa Tauer ,  Manfred Reiter ,  Wolfgang Mundt

IPC: C12Q001/37 ,  C12P021/06 ,  C12N007/00 ,  C12P001/00 ,  C12N009/76 ,  C12N007/01 ,  C07K001/00

CPC classification number: C12N9/6427 ,  C07K14/36 ,  C12N7/00 ,  C12N2760/16051 ,  C12N2760/16151 ,  C12N2770/32451

Abstract: The present invention provides methods of isolation and purification of Strepomyces griseus trypsin (SGT) from pronase in a single affinity chromatography step and uses of the purified SGT.

Abstract translation: 本发明提供了在单一亲和色谱步骤中从链霉蛋白酶分离和纯化灰葡萄球菌胰蛋白酶（SGT）的方法以及纯化的SGT的用途。

公开(公告)号：US20030124096A1

公开(公告)日：2003-07-03

申请号：US10260451

申请日：2002-10-01

Applicant: Western Health Care Network

Inventor： Stephen A. Locarnini ,  Angeline I. Bartholomeusz ,  Thein T. Aye ,  Robert A. de Man

IPC: C12Q001/70 ,  C07H021/04 ,  C12N009/22 ,  C12N007/00 ,  A01N063/00 ,  A01N065/00 ,  A61K048/00 ,  C12N007/01

CPC classification number: C12N7/00 ,  C07K14/005 ,  C12N9/1276 ,  C12N2730/10122

Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes.

Abstract translation: 本发明一般涉及对特定试剂表现出降低的敏感性和/或降低与免疫试剂的相互作用的病毒变体。 更具体地，本发明涉及对核苷类似物表现出完全或部分抗性和/或与病毒表面组分的抗体降低的相互作用的乙型肝炎变体。 本发明还考虑了用于检测这种病毒变体的测定法，该测定可用于监测抗病毒治疗方案。

公开(公告)号：US20030119165A1

公开(公告)日：2003-06-26

申请号：US10301064

申请日：2002-11-21

Inventor： Rebecca E. Cahoon ,  Guihua Lu ,  Mark E. Williams

IPC: C12N009/22 ,  C07H021/04 ,  C12N007/01 ,  C12N005/04 ,  C12P021/02 ,  C12N001/21

CPC classification number: C07K14/415 ,  C12N15/8216

Abstract: This invention relates to an isolated nucleic acid fragment encoding a transcription factor. The invention also relates to the construction of a chimeric gene encoding all or a portion of the transcription factor, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the transcription factor in a transformed host cell.

Abstract translation: 本发明涉及编码转录因子的分离的核酸片段。 本发明还涉及在正义或反义方向上编码全部或部分转录因子的嵌合基因的构建，其中嵌合基因的表达导致转化宿主细胞中转录因子水平的变化。

公开(公告)号：US20030119029A1

公开(公告)日：2003-06-26

申请号：US10217878

申请日：2002-08-13

Applicant: Regents of the University of Michigan

Inventor： Gary D. Glick ,  Anthony W. Opipari

IPC: A61K031/5513 ,  C12Q001/68 ,  A61K031/55 ,  A01N043/62 ,  C12N007/00 ,  C12N007/01 ,  C12N005/00 ,  C12N005/02

CPC classification number: C07D401/12 ,  A61K31/551 ,  A61K31/5513 ,  C07D243/14 ,  C07D243/24 ,  C07D403/12 ,  C07D413/12

Abstract: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.

Abstract translation: 本发明涉及新型化合物，其发现方法及其治疗用途。 特别地，本发明提供了苯并二氮杂衍生物和使用苯并二氮杂衍生物作为治疗剂治疗与程序性细胞死亡，自身免疫，炎症和过度增殖等过程的错误调节相关的多种病症的方法。

公开(公告)号：US20030118611A1

公开(公告)日：2003-06-26

申请号：US10073834

申请日：2002-02-11

Applicant: University of Washington

Inventor： David M. Koelle ,  Lawrence Corey

IPC: A61K039/245 ,  A61K039/12 ,  C07H021/04 ,  C07K014/035 ,  C12P021/06 ,  C12P021/04 ,  A61K039/00 ,  C12N007/00 ,  C12N007/01 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C07K001/00 ,  C07K014/00 ,  C07K017/00

CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K2039/55572 ,  A61K2039/57 ,  C07K2319/00 ,  C12N2710/16622 ,  C12N2710/16634

Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.